Hype, not hope – A comment on Ruberg et al. (2023) “Application of Bayesian approaches in drug development: starting a virtuous cycle”
Wilmar Igl, PhD1 & John Constant, PhD2 1Biostatistics Consulting Services, ICON PLC, Sweden2Scientific Affairs, ICON PLC, Canada “It’s about getting things down to one number.Using the stats the way we read them,we’ll find value in players that no one else can see.”Peter Brand, Moneyball [1] Introduction Ruberg et al.2 have recently published a perspective on…